MSB Trading 2022, The TurnAround, page-730

@ddwn, he had a very short time frame in which to present, I think he went with the lowest hanging fruit and the products that are closest to approval and that have the easiest to explain stories:

• AGVHD? Resubmitting next quarter after 9-1 win, we have info to overcome CMC and potency issues, approval this year.
• Back pain (every punter can relate)? Incredible success on target group, easy Phase 4 coming up, already okayed by FDA and will be in EU, too.
• Crohn's/IBD? 100% remission on test subjects, placebo "victims" getting Rem-L now, too, will update shortly, but expect blockbuster results.

SO CLEAR!

COVID? Hmm, only shown to work on under 65s, waiting for an unnamed partner (suspected to be NIH) to pay for it, FDA to agree on trial, but potency assays and the trial are fully reliant on AGVHD getting the nod for the same issues.

CHF? Hmm, incredible results...but ANOTHER multi-year trial likely required. Yes, we got asked by the FDA to submit extra info, and that was pretty exciting...but presumably, NO news from the FDA yet means you really cannot "sell" that one yet (a published NEJM article would have given an easier point to trumpet).

SO NOT CLEAR.

I think SI did an incredible job with the time he had, and with keeping things simple and approachable for the uninitiated. Anyone looking a bit more closely at MSB after the preso can easily find the CHF and COVID stuff on their own.